Jumonji Domain-Containing Histone Demethylases
"Jumonji Domain-Containing Histone Demethylases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of histone demethylases that share a conserved Jumonji C domain. The enzymes function via an iron-dependent dioxygenase mechanism that couples the conversion of 2-oxoglutarate to succinate to the hydroxylation of N-methyl groups.
Descriptor ID |
D056484
|
MeSH Number(s) |
D08.811.682.662.582.475.500 D08.811.682.690.416.388
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Jumonji Domain-Containing Histone Demethylases".
Below are MeSH descriptors whose meaning is more specific than "Jumonji Domain-Containing Histone Demethylases".
This graph shows the total number of publications written about "Jumonji Domain-Containing Histone Demethylases" by people in this website by year, and whether "Jumonji Domain-Containing Histone Demethylases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2019 | 1 | 1 | 2 |
2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Jumonji Domain-Containing Histone Demethylases" by people in Profiles.
-
Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15. Cancer Biol Ther. 2022 12 31; 23(1):65-75.
-
The histone demethylase JMJD2B is critical for p53-mediated autophagy and survival in Nutlin-treated cancer cells. J Biol Chem. 2019 06 07; 294(23):9186-9197.
-
JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells. Oncogene. 2019 07; 38(28):5643-5657.